EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
16 Feb 2024
16 Feb 2024
Historique:
received:
22
05
2023
accepted:
15
01
2024
medline:
17
2
2024
pubmed:
17
2
2024
entrez:
16
2
2024
Statut:
epublish
Résumé
Arcagen (NCT02834884) is a European prospective study aiming at defining the molecular landscape of rare cancers for treatment guidance. We present data from the cohort of rare thoracic tumors. Patients with advanced pleural mesothelioma (PM) or thymic epithelial tumors (TET) underwent genomic profiling with large targeted assay [>300 genes, tumor mutational burden (TMB), microsatellite instability (MSI) status] on formalin-fixed paraffin-embedded (FFPE) or plasma samples. EORTC molecular tumor board (MTB) advised for biomarker-guided treatments. 102 patients recruited from 8 countries between July 2019 and May 2022 were evaluable: 56 with PM, 46 with TET (23 thymomas, 23 thymic carcinomas). Molecular profiling was performed on 70 FFPE samples (42 PM, 28 TET), and 32 cases on ctDNA (14 PM, 18 TET), within a median turnaround time of 8 days from sample reception. We detected relevant molecular alterations in 66 out of 102 patients (65%; 79% PM, 48% TET), 51 of 70 FFPE samples (73%; 90% PM, 46% TET), and 15 of 32 plasma samples (47%; 43% PM, 50% TET). The most frequently altered genes were CDKN2A/B, BAP1, MTAP in PM and TP53, CDKN2A/B, SETD2 in TET. The TMB was low (mean 3.2 Muts/MB), 2 PM had MSI-high status. MTB advised molecular-guided treatment options in 32 situations, for 17 PM and 15 TET patients (75% clinical trial option, 22% off-label drug or compassionate use, 3% early access program). Molecular testing and MTB discussion were feasible for patients with rare thoracic cancers and allowed the broadening of treatment options for 30% of the cases.
Identifiants
pubmed: 38366021
doi: 10.1038/s41698-024-00518-9
pii: 10.1038/s41698-024-00518-9
doi:
Types de publication
Journal Article
Langues
eng
Pagination
37Informations de copyright
© 2024. The Author(s).
Références
Nuyts, V., Nawrot, T., Nemery, B. & Nackaerts, K. Hotspots of malignant pleural mesothelioma in Western Europe. Transl. Lung Cancer Res. 7, 516–519 (2018).
doi: 10.21037/tlcr.2018.10.01
pubmed: 30450289
pmcid: 6204417
Dumoulin, D. W., Bironzo, P., Passiglia, F., Scagliotti, G. V. & Aerts, J. G. J. V. Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours. Eur. Respir. Rev. 32, 220174 (2023).
doi: 10.1183/16000617.0174-2022
pubmed: 36754434
pmcid: 9910338
Zalcman, G. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387, 1405–1414 (2016).
doi: 10.1016/S0140-6736(15)01238-6
pubmed: 26719230
Peters, S. et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann. Oncol. 33, 488–499 (2022).
doi: 10.1016/j.annonc.2022.01.074
pubmed: 35124183
Tagliamento, M. et al. Meta-analysis on the combination of chemotherapy with programmed death-ligand 1 and programmed cell death protein 1 blockade as first-line treatment for unresectable pleural mesothelioma. J. Thorac. Oncol. S1556086423007244 https://doi.org/10.1016/j.jtho.2023.08.004 (2023).
Engels, E. A. Epidemiology of thymoma and associated malignancies. J. Thorac. Oncol. 5, S260–S265 (2010).
doi: 10.1097/JTO.0b013e3181f1f62d
pubmed: 20859116
pmcid: 2951303
Girard, N., Ruffini, E., Marx, A., Faivre-Finn, C. & Peters, S. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26, v40–v55 (2015).
doi: 10.1093/annonc/mdv277
pubmed: 26314779
Girard, N. et al. Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers. Oncologist 27, 919–929 (2022).
doi: 10.1093/oncolo/oyac115
pubmed: 35749302
pmcid: 9632319
Guo, G. et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 75, 264–269 (2015).
doi: 10.1158/0008-5472.CAN-14-1008
pubmed: 25488749
Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016).
doi: 10.1038/ng.3520
pubmed: 26928227
Hmeljak, J. et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 8, 1548–1565 (2018).
doi: 10.1158/2159-8290.CD-18-0804
pubmed: 30322867
pmcid: 6310008
Hiltbrunner, S. et al. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br. J. Cancer 127, 1997–2005 (2022).
doi: 10.1038/s41416-022-01979-0
pubmed: 36138075
pmcid: 9681755
Creaney, J. et al. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. Genome Med. 14, 58 (2022).
doi: 10.1186/s13073-022-01060-8
pubmed: 35637530
pmcid: 9150319
Radovich, M. et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 33, 244–258.e10 (2018).
doi: 10.1016/j.ccell.2018.01.003
pubmed: 29438696
pmcid: 5994906
Dumbrava, E. E. et al. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C. Mutat. J. Clin. Oncol. 40, 3003–3003 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.3003
Dada, H. I., Drusbosky, L. & Giaccone, G. Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs). J. Clin. Oncol. 39, 8577–8577 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.8577
Bayle, A. et al. Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). Ann. Oncol. 33, 1328–1331 (2022).
doi: 10.1016/j.annonc.2022.08.089
pubmed: 36122799
Zhang, Y. et al. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nat. Commun. 12, 11 (2021).
doi: 10.1038/s41467-020-20162-8
pubmed: 33397889
pmcid: 7782482
Morfouace, M. et al. First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN. ESMO Open 5, e001075 (2020).
doi: 10.1136/esmoopen-2020-001075
pubmed: 33262201
pmcid: 7709508